Wednesday, January 20, 2016 - Friday, January 20, 2017 12:00 AM
At the conclusion of this course, participants should be able to:
- Identify risk factors for transmission of hepatitis C virus (HCV);
- Recall the pathophysiology of HCV infection and the consequence of chronic disease progression;
- List new direct-acting antivirals (DAAs), the mechanism of action and associated side effects; and
- Explore issues surrounding the high cost of HCV infection treatment.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Indiana University School of Medicine and Indiana University Health Bloomington Hospital. The Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Indiana University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.